Xiaojia Wang

8.2k total citations · 2 hit papers
150 papers, 2.7k citations indexed

About

Xiaojia Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xiaojia Wang has authored 150 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 45 papers in Cancer Research. Recurrent topics in Xiaojia Wang's work include HER2/EGFR in Cancer Research (51 papers), Advanced Breast Cancer Therapies (43 papers) and Cancer Treatment and Pharmacology (32 papers). Xiaojia Wang is often cited by papers focused on HER2/EGFR in Cancer Research (51 papers), Advanced Breast Cancer Therapies (43 papers) and Cancer Treatment and Pharmacology (32 papers). Xiaojia Wang collaborates with scholars based in China, United States and South Korea. Xiaojia Wang's co-authors include Wen‐Ming Cao, Xian Wang, Zefei Jiang, Hongchuan Jin, Jifeng Feng, Zhongsheng Tong, Xiaoying Lin, Qingyuan Zhang, Yu‐An Huang and Xiying Shao and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Xiaojia Wang

137 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

2024 68 citations Yabing Zheng, Xiaojia Wang et al. Breast Cancer profile →
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Xiaojia Wang

Since Specialization

Citations

This map shows the geographic impact of Xiaojia Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojia Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojia Wang more than expected).

Fields of papers citing papers by Xiaojia Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojia Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojia Wang. The network helps show where Xiaojia Wang may publish in the future.

Co-authorship network of co-authors of Xiaojia Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojia Wang. A scholar is included among the top collaborators of Xiaojia Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojia Wang. Xiaojia Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial breakdown → 2025 ·Nature Medicine ·Yongmei Yin, Ying Fan, (unknown), (unknown), Xiaojia Wang, Wěi Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, (unknown), (unknown), Zhongsheng Tong, (unknown), (unknown), Xiaoping Jin, (unknown), (unknown), Binghe Xu	16
2	Revealing the Veil of Greenwashing in ESG Reports: Predicting the Degree of Corporate Greenwashing Based on Thematic and Sentiment Features of Text 2025 ·IEEE Transactions on Sustainable Computing ·Xiaojia Wang, Chen Ya, Haipeng Yao	0
3	Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial 2025 ·Nature Communications ·Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, (unknown), Xinlan Liu, (unknown), Bing Zhao, Shusen Wang, Xiaohua Zeng, (unknown), (unknown), Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, (unknown), Deyong Zhang, Tong Li	2
4	A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. 2024 ·Journal of Clinical Oncology ·Xiying Shao, Ming Kuang, Zhanhong Chen, Yabing Zheng, Guangliang Li, (unknown), Ping Huang, Wen‐Ming Cao, Lixia Xu, Xiaojia Wang	1
5	Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study 2024 ·Breast Cancer ·Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Naoki Niikura, Winnie Yeo, Keun Seok Lee, Yee Soo Chae, Binghe Xu, Xiaojia Wang, Seock‐Ah Im, Wěi Li, Yen‐Shen Lu, (unknown), (unknown), Yuji Nishiyama, Masahiro Sugihara, Shanu Modi, Junji Tsurutani	6
6	Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy 2023 ·PubMed ·Xiaojia Wang, Wěi Li, Yongmei Yin, Zhongsheng Tong, Qingyuan Zhang, Hong Zheng, (unknown), Huiping Li, Yang Jin, Jifeng Feng, Fan Wu, (unknown), Eleonora Restuccia, Zefei Jiang	4
7	κ−Carrageenan−Based flexible antibacterial and pH−Sensitive hydrogels with phenanthroline covalent conjugation groups 2023 ·Food Hydrocolloids ·Xiaojia Wang, Nana Sun, (unknown), Yina Yang, Guoqiao Lai, Xiongfa Yang	12
8	A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer 2023 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Yifan Zhu, (unknown), Rong Wang, Xiaolin Li, (unknown), Xiaowen Ding, Xiaojia Wang, Wen‐Ming Cao	3
9	Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study) 2023 ·European Journal of Cancer ·Jiayu Wang, Li Cai, Yanqiu Song, Tong Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu	7
10	Utility of clinical metagenomics in diagnosing malignancies in a cohort of patients with Epstein-Barr virus positivity 2023 ·Frontiers in Cellular and Infection Microbiology ·Jieyu Song, (unknown), Xiaojia Wang, (unknown), (unknown), Yi Zhang, Zhangfan Fu, Hongyu Wang, Yuanhan Zhao, Ke Lin, (unknown), Jingxin Guo, Yingqi Shi, Chao Liu, Jingwen Ai, H. C. Zhang, Wenhong Zhang	8
11	A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments 2023 ·International Journal of Cancer ·Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wěi Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, (unknown), Xiuyu Julie Cong, (unknown)	27
12	Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study 2023 ·International Journal of Cancer ·Yiqun Li, Zhongsheng Tong, (unknown), Quchang Ouyang, Li Cai, Wěi Li, Zhiyong Yu, Zhengxiang Han, Xiaojia Wang, Man Li, Haibo Wang, Li Li, Jin Yang, (unknown), (unknown), Binghe Xu	5
13	Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial 2023 ·Nature Communications ·Yabing Zheng, Wen‐Ming Cao, Xiying Shao, Yanxia Shi, Li Cai, Wenyan Chen, Jian Liu, Peng Shen, Yiding Chen, Xian Wang, Huiping Li, Man Li, Zhanhong Chen, Xiaojia Wang	10
14	The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer 2022 ·Technology in Cancer Research & Treatment ·(unknown), Jiayi Wu, (unknown), Xiying Shao, Xiaojia Wang	0
15	Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review 2022 ·Medicine ·Jiayi Wu, (unknown), Xiying Shao, (unknown), Xiaojia Wang	0
16	BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis 2021 ·Journal of Breast Cancer ·(unknown), (unknown), (unknown), Xiaojia Wang, Wen‐Ming Cao	5
17	Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. 2014 ·PubMed ·Xiying Shao, Xian Wang, Xiaohong Xu, (unknown), Mark Han, Han Zhang, Zhanhong Chen, (unknown), (unknown), Huang Ping, Hongchuan Jin, Xiaojia Wang	6
18	The interactions between the truncated fragments of ARM repeat conaining (ARC1) from Brassica oleracea var. acephala L and kinase domain of S-receptor kinase (SRK) from B. oleracea var. capitata L tested by a yeast two-hybrid system. 2011 ·Journal of Pharmaceutical and Biomedical Sciences ·(unknown), Kun Yang, Liquan Zhu, (unknown), (unknown), Yang Hong, (unknown), (unknown), (unknown), (unknown), Xiaojia Wang	2
19	Molecular identification of Brassica oleracea CMS and the morphology response of flower to nuclear background. 2010 ·Acta Horticulturae Sinica ·Zhang Yan, Xiaojia Wang, (unknown), Hongyuan Song, (unknown), (unknown)	7
20	Rapid Identification of Self-incompatibility and S-alleles of Cabbage by the Polymorphism of S Locus 2000 ·Zhiwu xuebao ·Liquan Zhu, Xiaojia Wang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact